Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 29, 2026.
Quick answer
On April 22, 2026, FDA removed BPC-157 from its Category 2 list because the nomination was withdrawn, not because FDA found it safe. On October 30, 2026, HHS published a draft policy (proposed, not final) that names BPC-157. It is not binding and it is not FDA approval.
FDA status: Not FDA-approved for any use in people. Source: FDA .
Last reviewed November 1, 2026 by the PeptideX team. Educational info, not medical advice. PeptideX doesn't give dosing advice. Talk to a licensed clinician.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Animal Only. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 544 PubMed citations indexed.
Products sold as "research use only" are not approved for human use. FDA warning.
Activates VEGFR2/Akt-eNOS axis promoting angiogenesis and endothelial repair; modulates ERK1/2 signaling and suppresses pro-inflammatory cytokines.
What the literature studies
Tissue Repair & Cytoprotection
Evidence tier
Animal Only
Compounding record
HHS proposed 503A enforcement discretion (not final)
HHS proposed 503A enforcement discretion (not final). FDA substance context: BPC-157. Named in the proposed HHS 503A enforcement-discretion notice (Federal Register 2026-22192, October 2026). The policy is proposed, not final, and is not FDA approval. FDA's earlier record lists the nomination as withdrawn from Category 2 with potential significant safety risks. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 29, 2026. This compounding label is separate from the approval line above.
Regulatory context and verification limits are documented below.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.
BPC-157 is an unapproved lab peptide with a big animal literature and almost no human data - 3 tiny studies, 30 people total - and its US legal status may shift soon via an FDA interim compounding policy that isn't public yet.
A synthetic peptide ("Body Protection Compound-157"), sold online as a "research chemical" and nicknamed "Wolverine" [REUT]. In FDA's July 2026 review, the use evaluated was ulcerative colitis - not tendon or muscle repair [FDA-BPC].
FDA compounding status (checked Oct 27 2026): BPC-157 is not FDA-approved for any use. FDA's safety-risk page lists it under "bulk drug substances nominated but withdrawn" (previously Category 2) [FDA-RISK]. The nomination was withdrawn, but FDA evaluated it on its own initiative for its Jul 23-24 2026 Pharmacy Compounding Advisory Committee; FDA's briefing document concluded the evidence weighs against placing it on the 503A bulks list [FDA-BPC]. The committee voted 8-6 (1 abstention) in favor anyway - advisory only; adding it would still require notice-and-comment rulemaking [AJMC]. On Oct 14 2026 FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) to White House review; its text and covered peptides are not public, and OMB meetings on it are listed for Oct 27-28 [OIRA]. The AP reported, citing unnamed sources, that BPC-157 is among peptides the interim policy would cover [AP].
Dozens of rodent studies report faster tendon, ligament, muscle and gut healing [R4]. Animal results are not evidence of effect in people; FDA reviewers called the available studies short, small and insufficient to establish safety or effectiveness [AJMC].
Is BPC-157 safe for humans?
Its safety in people has not been established. A 2026 systematic review found only three small human studies (30 people total), all rated poor quality, with "very low" certainty of evidence. Its authors said BPC-157 should not be used clinically outside regulated, high-quality clinical trials. [1]
What do human studies actually show?
The three studies were a retrospective knee-pain series, a retrospective bladder (interstitial cystitis) pilot, and a 2-person IV safety pilot. They had no control groups. Small uncontrolled studies cannot show that something is safe or that it works. [1]
Why do people say it's safe?
Most data come from animal studies. A 2025 systematic review found 35 preclinical studies and 1 clinical study, and "no clinical safety data" in humans. Animal results often don't carry over to people. [2]
What is FDA's position on BPC-157?
BPC-157 is not FDA-approved for any use. It was in FDA's Category 2 from September 2023 until April 22, 2026; FDA's page now lists it under "nominated but withdrawn." FDA says compounded BPC-157 may pose a risk of immune reactions for certain routes, and that it has found no, or only limited, safety information. [3][4] HHS has also published a draft policy (proposed, not final) that names BPC-157 among six peptides licensed pharmacies could compound under set conditions. [4] Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. [4]
What are the risks with vials sold online?
The 2025 review warns adverse effects are possible from "unregulated manufacturing, contamination, or unknown clinical safety." [2] HHS's draft policy describes "research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients," and would require lot-level testing for identity, purity and contaminants such as endotoxins. [4] A product labeled "research use only" is not made for people.
Is BPC-157 prohibited in sport?
Yes. BPC-157 is prohibited by WADA: the 2026 Prohibited List names it under S0, Non-Approved Substances, prohibited at all times. Athletes should also check their own organization's rules. [5]
Talk to a licensed clinician before using any unapproved peptide.
Last checked 2026-10-27
Education only. Not medical advice. No dosing guidance. peptidex.ai does not sell peptides or link to sellers.